MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, selling common stock and pre-funded warrants to institutional investors. The funds will support general corporate purposes, including a $45 million payment linked to the recent FDA approval of their drug Furoscix ReadyFlow™, an autoinjector for treating edema in heart failure and chronic kidney disease. The financing is expected to close around July 24, 2026, and MannKind plans to register the resale of these securities with the SEC. This capital raise aims to strengthen MannKind's position as it advances treatments for cardiometabolic and orphan lung diseases.
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
VinFast Auto Ltd. is set to release its Q3 2026 earnings with analysts expecting a loss per share of $0.33 and revenues around $1.15 billion. The Vietnamese electric vehicle maker is expanding internationally, promoting its VF 9 SUV in Canada and ben...
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
Michael Saylor, Executive Chairman of Strategy, stated that advocating for Bitcoin in the US is protected free speech and does not require a financial license. He emphasized that Bitcoin is considered a commodity, not a security, and legitimate promo...
Bitcoin's price rose nearly 1% to around $79,262 on September 4, extending a one-month rally of about 23%. Simultaneously, gold prices climbed sharply, pushing their correlation to the highest level in six years. This trend reflects growing investor ...
